Confronto

BPC-157 vs. TB-500

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Guarigione

N. CAS

137525-51-0

nessun dato

Peso molecolare

1419.5 g/mol

888 g/mol

Emivita

4 h

nessun dato

Sequenza

GEPPPGKPADDAGLV

Ac-LKKTETQ

Meccanismo d'azione

BPC-157

Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Base di evidenze

Evidenza più alta

Modello animale

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	BPC-157	TB-500
Australia	Vietato	Vietato
Svizzera	Non approvato	—
Germania	Non approvato	Non approvato
Stati Uniti	Solo ricerca	Solo ricerca

Voci complete

Frequently asked questions

What is the difference between BPC-157 and TB-500?: BPC-157 is classified as "Guarigione", while TB-500 is classified as "Guarigione". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, BPC-157 or TB-500?: The highest available evidence level is "Modello animale" for BPC-157 and "Modello animale" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of BPC-157 and TB-500 in Germany and the United States?: Germania: BPC-157 — Non approvato, TB-500 — Non approvato. Stati Uniti: BPC-157 — Solo ricerca, TB-500 — Solo ricerca. These are factual summaries with source and review date on the individual pages.

Country

BPC-157

TB-500

Australia

Vietato

Svizzera

Non approvato

—

Germania

Non approvato

Stati Uniti

Solo ricerca

Frequently asked questions

What is the difference between BPC-157 and TB-500?

BPC-157 is classified as "Guarigione", while TB-500 is classified as "Guarigione". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, BPC-157 or TB-500?

The highest available evidence level is "Modello animale" for BPC-157 and "Modello animale" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of BPC-157 and TB-500 in Germany and the United States?

Germania: BPC-157 — Non approvato, TB-500 — Non approvato. Stati Uniti: BPC-157 — Solo ricerca, TB-500 — Solo ricerca. These are factual summaries with source and review date on the individual pages.